scholarly journals Bacteriophages against Vibrio coralliilyticus and Vibrio tubiashii: Isolation, Characterization and Remediation of Larval Oyster Mortalities

Author(s):  
Gary P. Richards ◽  
Michael A. Watson ◽  
David Madison ◽  
Nitzan Soffer ◽  
David S. Needleman ◽  
...  

Vibrio coralliilyticus and Vibrio tubiashii are pathogens responsible for high larval oyster mortalities in shellfish hatcheries. Bacteriophage therapy was evaluated to determine its potential to remediate these mortalities. Sixteen phages against V. coralliilyticus and V. tubiashii were isolated and characterized from Hawaiian seawater. Fourteen isolates were members of the Myoviridae family and two were Siphoviridae. In proof-of-principle trials, a cocktail of five phages reduced mortalities of larval Eastern oysters (Crassostrea virginica) and Pacific oysters (Crassostrea gigas) by up to 91% at 6 days post-challenge with lethal doses of V. coralliilyticus. Larvae survival depended on the oyster species, the quantity of phages and vibrios applied, and the species and strain of Vibrio. A later-generation cocktail, designated VCP300, was formulated with three lytic phages subsequently named Vibrio phage vB_VcorM-GR7B; vB_VcorM-GR11A, and vB_VcorM-GR28A (abbreviated 7B, 11A and 28A). Together, these three phages displayed host specificity toward eight V. coralliilyticus strains and a V. tubiashii strain. Larval C. gigas mortalities from V. coralliilyticus strains RE98 and OCN008 were significantly reduced by > 90% (P < 0.0001) over 6 days with phage treatment compared to untreated controls. Genomic sequencing of phages 7B, 11A and 28A revealed 207,758; 194,800; and 154,046 bp, linear DNA genomes, respectively, with the latter showing 92% similarity to V. coralliilyticus phage YC, a strain from the Great Barrier Reef, Australia. Phage 7B and 11A genomes showed little similarity to phages in the NCBI database. This study demonstrates the promising potential for phage therapy to reduce larval oyster mortalities in oyster hatcheries. IMPORTANCE Shellfish hatcheries encounter episodic outbreaks of larval oyster mortalities, jeopardizing the economic stability of the hatcheries and commercial shellfish industry. Shellfish pathogens, like Vibrio coralliilyticus and Vibrio tubiashii, have been recognized as major contributors of larval oyster mortalities in U.S. East and West Coast hatcheries for many years. This study isolated, identified, and characterized bacteriophages against these Vibrio species, and demonstrated their ability to reduce mortalities from V. coralliilyticus in larval Pacific oysters and both V. coralliilyticus and V. tubiashii in larval Eastern oysters. Phage therapy offers a promising approach in stimulating hatchery production to ensure the well-being of hatcheries and the commercial oyster trade.

2014 ◽  
Vol 81 (1) ◽  
pp. 292-297 ◽  
Author(s):  
Gary P. Richards ◽  
Michael A. Watson ◽  
David S. Needleman ◽  
Karlee M. Church ◽  
Claudia C. Häse

ABSTRACTVibrio tubiashiiis reported to be a bacterial pathogen of larval Eastern oysters (Crassostrea virginica) and Pacific oysters (Crassostrea gigas) and has been associated with major hatchery crashes, causing shortages in seed oysters for commercial shellfish producers. Another bacterium,Vibrio coralliilyticus, a well-known coral pathogen, has recently been shown to elicit mortality in fish and shellfish. Several strains ofV. coralliilyticus, such as ATCC 19105 and Pacific isolates RE22 and RE98, were misidentified asV. tubiashiiuntil recently. We compared the mortalities caused by twoV. tubiashiiand fourV. coralliilyticusstrains in Eastern and Pacific oyster larvae. The 50% lethal dose (LD50) ofV. coralliilyticusin Eastern oysters (defined here as the dose required to kill 50% of the population in 6 days) ranged from 1.1 × 104to 3.0 × 104CFU/ml seawater; strains RE98 and RE22 were the most virulent. This study shows thatV. coralliilyticuscauses mortality in Eastern oyster larvae. Results for Pacific oysters were similar, with LD50s between 1.2 × 104and 4.0 × 104CFU/ml.Vibrio tubiashiiATCC 19106 and ATCC 19109 were highly infectious toward Eastern oyster larvae but were essentially nonpathogenic toward healthy Pacific oyster larvae at dosages of ≥1.1 × 104CFU/ml. These data, coupled with the fact that several isolates originally thought to beV. tubiashiiare actuallyV. coralliilyticus, suggest thatV. coralliilyticushas been a more significant pathogen for larval bivalve shellfish thanV. tubiashii, particularly on the U.S. West Coast, contributing to substantial hatchery-associated morbidity and mortality in recent years.


Antibiotics ◽  
2021 ◽  
Vol 10 (6) ◽  
pp. 675
Author(s):  
Saartje Uyttebroek ◽  
Jolien Onsea ◽  
Willem-Jan Metsemakers ◽  
Lieven Dupont ◽  
David Devolder ◽  
...  

Chronic rhinosinusitis is a common condition affecting 5–12% of the general population worldwide. In a limited number of cases, the disease is recalcitrant to medical and surgical interventions, causing a major impact on physical, social and emotional well-being and increasing pressure on healthcare systems. Biofilm formation and dysbiosis caused by Staphylococcus aureus and Pseudomonas aeruginosa play a role in the pathogenesis of recalcitrant chronic rhinosinusitis. In these cases, a promising treatment alternative is the application of bacteriophages, which are viruses that infect and lyse bacteria. In this review, we appraise the evidence for the use of bacteriophages in the treatment of recalcitrant chronic rhinosinusitis. Additionally, (dis)advantages of bacteriophages and considerations for implementation of phage therapy in otorhinolaryngology practice will be discussed.


Microbiome ◽  
2021 ◽  
Vol 9 (1) ◽  
Author(s):  
Andre Mu ◽  
Daniel McDonald ◽  
Alan K. Jarmusch ◽  
Cameron Martino ◽  
Caitriona Brennan ◽  
...  

Abstract Background Infectious bacterial diseases exhibiting increasing resistance to antibiotics are a serious global health issue. Bacteriophage therapy is an anti-microbial alternative to treat patients with serious bacterial infections. However, the impacts to the host microbiome in response to clinical use of phage therapy are not well understood. Results Our paper demonstrates a largely unchanged microbiota profile during 4 weeks of phage therapy when added to systemic antibiotics in a single patient with Staphylococcus aureus device infection. Metabolomic analyses suggest potential indirect cascading ecological impacts to the host (skin) microbiome. We did not detect genomes of the three phages used to treat the patient in metagenomic samples taken from saliva, stool, and skin; however, phages were detected using endpoint-PCR in patient serum. Conclusion Results from our proof-of-principal study supports the use of bacteriophages as a microbiome-sparing approach to treat bacterial infections.


2011 ◽  
Vol 26 (S1) ◽  
pp. s96-s96
Author(s):  
P. Hollier

Animal production is an important component to economic stability and food security in developing country. Economic development programs have targeted agriculture in developing country as a means of decreasing poverty and empowering vulnerable populations throughout much of the developing world. Disasters due to natural and man-made hazards that impact animal agriculture have a disproportionate impact on the rural poor and vulnerable populations affecting the economic well being and health of the greater population. Protection of livelihoods dependent on animal agriculture is important to consider in community resilience and humanitarian assistance activities that range from capacity building through response and recovery. In order to meet the challenges of the next generation of global health threats, policy, research, and practice must adopt a new cross-cutting approach that targets the human-animal-ecologic interface taking into account political, socioeconomic, and cultural factors.


2020 ◽  
Vol 287 (1920) ◽  
pp. 20192882 ◽  
Author(s):  
Maya Wardeh ◽  
Kieran J. Sharkey ◽  
Matthew Baylis

Diseases that spread to humans from animals, zoonoses, pose major threats to human health. Identifying animal reservoirs of zoonoses and predicting future outbreaks are increasingly important to human health and well-being and economic stability, particularly where research and resources are limited. Here, we integrate complex networks and machine learning approaches to develop a new approach to identifying reservoirs. An exhaustive dataset of mammal–pathogen interactions was transformed into networks where hosts are linked via their shared pathogens. We present a methodology for identifying important and influential hosts in these networks. Ensemble models linking network characteristics with phylogeny and life-history traits are then employed to predict those key hosts and quantify the roles they undertake in pathogen transmission. Our models reveal drivers explaining host importance and demonstrate how these drivers vary by pathogen taxa. Host importance is further integrated into ensemble models to predict reservoirs of zoonoses of various pathogen taxa and quantify the extent of pathogen sharing between humans and mammals. We establish predictors of reservoirs of zoonoses, showcasing host influence to be a key factor in determining these reservoirs. Finally, we provide new insight into the determinants of zoonosis-sharing, and contrast these determinants across major pathogen taxa.


2011 ◽  
Vol 2 (1) ◽  
pp. 2 ◽  
Author(s):  
Guilherme Augusto Marietto Gonçalves ◽  
Edna Tereza Lima Lima ◽  
Tais Cremasco Donato ◽  
Ticiane Sousa Rocha ◽  
Luis Emiliano Cisneros Álvarez ◽  
...  

<span style="line-height: 150%;" lang="EN-US">It has been reported that the phage therapy is effective in controlling the number of colony-forming unit (CFU) of <em style="mso-bidi-font-style: normal;">Salmonella</em> spp. in chicken gut. This paper describes the protective effect of phage and <em style="mso-bidi-font-style: normal;">Lactobacilli</em> administration on <em style="mso-bidi-font-style: normal;">Salmonella</em> infection in 1-day-old chicks. We administered the bacteriophage P22 in a single dose and a probiotic mixture of four species of bacteriocin-producing <em style="mso-bidi-font-style: normal;">Lactobacillus</em> once a day for one week. Samples were analyzed every 48 hours, and intestinal eradication of <em style="mso-bidi-font-style: normal;">S.</em> Typhimurium was confirmed after treatments. We observed an increase in the size of duodenal villi and cecal crypts, as well as an increase in body weight in groups that received daily doses of <em style="mso-bidi-font-style: normal;">Lactobacilli</em>. </span><span style="line-height: 150%;" lang="EN-US">This study confirms the efficiency of bacteriophage therapy in controlling salmonellosis in chicks and the beneficial effect of <em style="mso-bidi-font-style: normal;">Lactobacilli</em> mixtures in the weight gain of the birds.<span style="mso-spacerun: yes;"> </span></span>


Author(s):  
Darien D. Mizuta ◽  
Gary H. Wikfors ◽  
Shannon L. Meseck ◽  
Yaqin Li ◽  
Mark S. Dixon ◽  
...  

Antibiotics ◽  
2019 ◽  
Vol 8 (3) ◽  
pp. 131 ◽  
Author(s):  
Ganeshan ◽  
Hosseinidoust

Bacteriophages are viruses that infect bacteria. After their discovery in the early 1900s, bacteriophages were a primary cure against infectious disease for almost 25 years, before being completely overshadowed by antibiotics. With the rise of antibiotic resistance, bacteriophages are being explored again for their antibacterial activity. One of the critical apprehensions regarding bacteriophage therapy, however, is the possibility of genome evolution, development of phage resistance, and subsequent perturbations to our microbiota. Through this review, we set out to explore the principles supporting the use of bacteriophages as a therapeutic agent, discuss the human gut microbiome in relation to the utilization of phage therapy, and the co-evolutionary arms race between host bacteria and phage in the context of the human microbiota.


2019 ◽  
Vol 55 (03) ◽  
pp. 151-158
Author(s):  
Gopal Nath ◽  
Ram Janam ◽  
Rajesh Kumar ◽  
Mayank Gangwar

AbstractThe present study was planned to evaluate the efficacy of Pseudomonas aeruginosa specific phages in immunocompromised septicemia animal model as an alternative to antibiotics. Five different sets of experiments were performed: prophylactic administration of phage cocktail (3 lytic and unique) before and simultaneous with bacterial challenge; and therapeutic, that is, administration of phage cocktail 6, 12, and 24 hours after the bacterial challenge. No mortality was observed when simultaneous and late administration of phages was done with respect to the bacterial challenge. Contrary to this, administration of phage cocktail 100 µL (1012 PFU/mL) of volume after 6 hours of the infection resulted in a mortality rate of 60%. However, no mortality could be observed with reduced dose of cocktail, that is, 108, 109, and 1010 PFU administered 6 hours after bacterial challenge. Phage therapy in acute infections initiated with very small dosage under strict supervision may give better results. However, further studies to determine the quantity and frequency of dosage of phage cocktail for septicemia of various durations is strongly indicated.


Viruses ◽  
2019 ◽  
Vol 11 (10) ◽  
pp. 891 ◽  
Author(s):  
Onsea ◽  
Soentjens ◽  
Djebara ◽  
Merabishvili ◽  
Depypere ◽  
...  

Bacteriophage therapy has recently attracted increased interest, particularly in difficult-to-treat infections. Although it is not a novel concept, standardized treatment guidelines are currently lacking. We present the first steps towards the establishment of a “multidisciplinary phage task force” (MPTF) and a standardized treatment pathway, based on our experience of four patients with severe musculoskeletal infections. After review of their medical history and current clinical status, a multidisciplinary team found four patients with musculoskeletal infections eligible for bacteriophage therapy within the scope of Article 37 of the Declaration of Helsinki. Treatment protocols were set up in collaboration with phage scientists and specialists. Based on the isolated pathogens, phage cocktails were selected and applied intraoperatively. A draining system allowed postoperative administration for a maximum of 10 days, 3 times per day. All patients received concomitant antibiotics and their clinical status was followed daily during phage therapy. No severe side-effects related to the phage application protocol were noted. After a single course of phage therapy with concomitant antibiotics, no recurrence of infection with the causative strains occurred, with follow-up periods ranging from 8 to 16 months. This study presents the successful outcome of bacteriophage therapy using a standardized treatment pathway for patients with severe musculoskeletal infection. A multidisciplinary team approach in the form of an MPTF is paramount in this process.


Sign in / Sign up

Export Citation Format

Share Document